Skip to main content
Amgen10-Q: Pricing pressure

ENBREL net selling price drops 22% due to Medicare price setting under the IRA.

What happened

Government regulation is directly impacting revenue, with ENBREL sales decreasing due to a 22% drop in net selling price from the Inflation Reduction Act (IRA). Otezla is also expected to face similar declines starting in 2027, forcing the company to manage significant margin compression on key products.

Source

SEC EDGARAug 4, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q

Filing excerpt

The decrease in ENBREL sales for the three months ended June 30, 2026 was primarily driven by lower net selling price of 22% resulting from the impact of U.S. Medicare Part D price setting under the IRA, effective January 1, 2026...

sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htmRead the full source

Other signals in this filing (7)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Pricing pressure

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
-22% (ENBREL lower net selling price for the quarter)

Details

CIK
318154
Accession number
0000318154-26-000126
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Cost optimization needed
Signal category
Market

Topics and mentions

Regions named

  • United States

Extraction

Confidence
High
Relevance
90%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
pricingPressure

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b87fb8c7-5ff2-4db4-9e3d-610ec8ef7ee8 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "b87fb8c7-5ff2-4db4-9e3d-610ec8ef7ee8",
  "signal_type": "sec-10q",
  "signal_subtype": "pricingPressure",
  "detected_at": "2026-08-11T08:11:01.218+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Government regulation is directly impacting revenue, with ENBREL sales decreasing due to a 22% drop in net selling price from the Inflation Reduction Act (IRA). Otezla is also expected to face similar declines starting in 2027, forcing the company to manage significant margin compression on key products.",
    "metrics": {
      "pct": -22,
      "timeframe": "current_quarter",
      "pct_context": "ENBREL lower net selling price for the quarter"
    },
    "summary": "ENBREL net selling price drops 22% due to Medicare price setting under the IRA.",
    "excerpts": "The decrease in ENBREL sales for the three months ended June 30, 2026 was primarily driven by lower net selling price of 22% resulting from the impact of U.S. Medicare Part D price setting under the IRA, effective January 1, 2026...",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm",
    "filing_date": "2026-08-04",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Cost optimization needed",
    "signal_category": "market",
    "regions_mentioned": [
      "United States"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.